Oak Harvest Investment Services Purchases 29,526 Shares of Boston Scientific Co. (NYSE:BSX)

Oak Harvest Investment Services grew its holdings in Boston Scientific Co. (NYSE:BSX) by 262.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 40,776 shares of the medical equipment provider’s stock after purchasing an additional 29,526 shares during the quarter. Oak Harvest Investment Services’ holdings in Boston Scientific were worth $3,642,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Values First Advisors Inc. acquired a new stake in Boston Scientific during the 3rd quarter worth $28,000. Dunhill Financial LLC grew its stake in shares of Boston Scientific by 86.4% during the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 152 shares during the period. Global Wealth Strategies & Associates increased its holdings in Boston Scientific by 423.7% in the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 250 shares during the last quarter. West Oak Capital LLC bought a new stake in shares of Boston Scientific in the 4th quarter valued at about $29,000. Finally, E Fund Management Hong Kong Co. Ltd. acquired a new stake in shares of Boston Scientific in the 3rd quarter valued at approximately $30,000. 89.07% of the stock is owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $90.78, for a total transaction of $633,916.74. Following the completion of the transaction, the executive vice president now directly owns 29,308 shares in the company, valued at $2,660,580.24. This represents a 19.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Edward J. Ludwig sold 4,877 shares of the business’s stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total transaction of $446,879.51. Following the sale, the director now directly owns 39,398 shares in the company, valued at approximately $3,610,038.74. The trade was a 11.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 29,989 shares of company stock valued at $2,702,261 in the last three months. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

Shares of NYSE:BSX opened at $102.97 on Friday. Boston Scientific Co. has a 12-month low of $62.63 and a 12-month high of $104.25. The company’s 50 day moving average price is $92.99 and its two-hundred day moving average price is $85.93. The firm has a market cap of $151.75 billion, a PE ratio of 85.10, a PEG ratio of 2.69 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. BTIG Research upped their target price on shares of Boston Scientific from $84.00 to $93.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Morgan Stanley lifted their target price on Boston Scientific from $92.00 to $100.00 and gave the stock an “overweight” rating in a report on Thursday, October 24th. Stifel Nicolaus increased their price target on Boston Scientific from $85.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Mizuho lifted their price objective on Boston Scientific from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Thursday, October 24th. Finally, Truist Financial raised their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. Two analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and a consensus target price of $97.26.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.